Clinical Trial Update: Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma [Phase 1]

View source ↗

Summary

The Phase 1 trial of a neoepitope-based personalized vaccine for newly diagnosed glioblastoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Grade Iv
• Glioblastoma

Drugs mentioned

• Neoepitope-based Personalized Vaccine

Snippet

Sponsor: Washington University School of Medicine | Conditions: Glioblastoma Multiforme, Astrocytoma, Grade IV | Phase 1 | Status: TERMINATED